Acumen Pharmaceuticals to Present at Upcoming Investor Conferences
09 November 2021 - 12:00AM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage
biopharmaceutical company focused on the development of novel
targeted therapeutics for Alzheimer’s disease (AD), today announced
that the company will participate in the following upcoming virtual
conferences:
- Credit Suisse 30th Annual
Healthcare Conference on Tuesday, November 9, 2021, at 9:40 AM
EST
- Stifel 2021 Healthcare Conference
on Tuesday, November 16, 2021, at 10:00 AM EST
Live audio webcasts will be available for on-demand viewing and
will be available on the Investors section of the company’s website
at www.acumenpharm.com. Replays will be available after the events
and archived on the Investors section of the company’s website at
www.acumenpharm.com for 30 days.
About Acumen Pharmaceuticals, Inc.Acumen
Pharmaceuticals, headquartered in Charlottesville, Va. with
clinical operations based in Carmel, Ind., is a clinical stage
biopharmaceutical company developing a novel disease-modifying
approach to treat Alzheimer’s disease. Acumen’s scientific founders
pioneered research on toxic soluble AβOs, which a growing body of
evidence indicates are primary triggers of Alzheimer’s disease
pathology. Acumen is currently focused on advancing its
investigational product candidate, ACU193, a humanized monoclonal
antibody that selectively targets toxic soluble AOs in a Phase 1
clinical trial involving early Alzheimer’s disease patients. For
more information, visit www.acumenpharm.com.
Contacts:
Media:AcumenPR@westwicke.com
Investors:investors@acumenpharm.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Apr 2023 to Apr 2024